Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 8;10(14):e34068.
doi: 10.1016/j.heliyon.2024.e34068. eCollection 2024 Jul 30.

Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma

Affiliations

Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma

Xin Wu et al. Heliyon. .

Abstract

Background: CD20 is a membrane protein extensively expressed on the surface of B cells at various stages of development and differentiation. Herein, we conducted a bibliometrics analysis of the literature on CD20-targeting antibody therapy in lymphoma.

Methods: A total of 6663 articles were downloaded from the web of science core collection (WOSCC) from 1999 to July 23, 2022. Bibliometric.com was used for citation and annual publications analysis. VOSviewer was used to map countries/institutions/authors/journals nodes and links, extract hotspot keywords, and analyze the time trend of keywords. Citespace was employed to recognize the turning points based on the centrality value of countries, define the topic distribution of academics according to the map of dual-map overlay of journals, and characterize the emerging topics or landmark articles in a field based on references citation bursts.

Results: All articles were cited 225,032 times, averaging 33.77. The number of articles increased from 1999 to 2002, while the growth rate entered the platform after 2002. The USA was the most publication country, and China was the largest emerging country. Hotspots in this field still focus on the efficacy of rituximab in treating non-Hodgkin's lymphoma and the pathogenesis of lymphoma Application of generation CD-20 antibodies or molecule inhibitors in clinical research and cellular therapy/immunotherapy, such as CAR-T and PDL1/PD1 were the emerging research topics.

Conclusion: This study provides essential information and the tendency of the CD20-targeting antibody therapy in lymphoma by using bibliometric and visual methods, which would provide helpful references for clinical experiments and basic scientific research.

Keywords: CD20; Combination therapy; Immunotherapy; Lymphoma; Rituximab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Number of publications of CD20-targeting antibody therapy in lymphoma A. Number of publications per year. B. The growth trend of publications in 1999–2002. C. The top 10 relative countries in the number of publications.
Fig. 2
Fig. 2
The number of citations of CD20-targeting antibody therapy in lymphoma. Exponential adjustment (a): y = 1042.1 e 0.1511x, R2 = 0.6517; Linear adjustment (b): y = 721.26x+887.26, R2 = 0.9226.
Fig. 3
Fig. 3
Countries and institutions contributed to CD20-targeting antibody therapy in lymphoma. A. The distribution of research area on CD20-targeting antibody therapy in lymphoma. B. The distribution of articles type of CD20-targeting antibody therapy in lymphoma.
Fig. 4
Fig. 4
Cooperation and citation relationship among countries and institutions. A: visualization of the top 10 countries with the highest number of articles. B: time-dependent overlay map of countries. C: overlay visualization of institutions. D: time-dependent overlay map of institutions.
Fig. 5
Fig. 5
Visualization map of co-authorship of authors A: network visualization of authors on CD20-targeting antibody therapy in lymphoma. B: time-dependent overlay visualization of authors on CD20-targeting antibody therapy in lymphoma.
Fig. 6
Fig. 6
Journal analysis on CD20-targeting antibody therapy in lymphoma. A: network visualization of journals B: time-dependent overlay visualization of journals C: dual-map overlay of journals. Notes: left side as citing journals, and right side as cited journals, the orange and green path means citations relationship. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 7
Fig. 7
Reference analysis on CD20-targeting antibody therapy in lymphoma. A: visualization of ten references with the highest citations. B: the top 50 references with the most robust bursts of citations.
Fig. 8
Fig. 8
Keywords analysis on CD20-targeting antibody therapy in lymphoma A: network visualization of journals B: time-dependent overlay visualization of journals C: dual-map overlay of journals. Notes: left side as citing journals, and right side as cited journals, the orange and green path means citations relationship. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 9
Fig. 9
Obinutuzumab combined with PD1 inhibitors acts synergistically for lymphoma. A: Cell apoptosis analysis for OCI-Ly8 cells. B: Cell apoptosis analysis for Daudi cells.
figs1
figs1

Similar articles

References

    1. Du A., Wu X., Gao Y., Jiang B., Wang J., et al. m6A Regulator-mediated Methylation Modification patterns and tumor microenvironment infiltration characterization in acute myeloid leukemia. Front. Immunol. 2021;12 - PMC - PubMed
    1. Jiang D., Wu X., Sun X., Tan W., Dai X., et al. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11. J Nanobiotechnology. 2022;20(1):29. - PMC - PubMed
    1. Wu X., Zhang X., Feng W., Feng H., Ding Z., et al. A targeted Erythrocyte membrane-encapsulated drug-delivery system with anti-osteosarcoma and anti-osteolytic effects. ACS Appl. Mater. Interfaces. 2021;13(24):27920–27933. - PubMed
    1. Wu Z., Zhang X., Chen D., Li Z., Wu X., et al. N6-Methyladenosine-Related LncRNAs are potential remodeling Indicators in the tumor microenvironment and prognostic Markers in osteosarcoma. Front. Immunol. 2021;12 - PMC - PubMed
    1. Xin Wu, Shiqin Li, Dongjie Chen, Guiping Zheng, Zhang Zhaohua, et al. An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia. Am J Transl Res. 2022 - PMC - PubMed

LinkOut - more resources